Market closed
Relmada Therapeutics/$RLMD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Relmada Therapeutics
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
Ticker
$RLMD
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
17
ISIN
US75955J4022
Website
RLMD Metrics
BasicAdvanced
$12M
-
-$2.65
0.41
-
Price and volume
Market cap
$12M
Beta
0.41
52-week high
$4.47
52-week low
$0.24
Average daily volume
3M
Financial strength
Current ratio
4.45
Quick ratio
4.364
Management effectiveness
Return on assets (TTM)
-73.14%
Return on equity (TTM)
-132.33%
Valuation
Price to book
0.31
Price to tangible book (TTM)
0.31
Price to free cash flow (TTM)
-0.212
Growth
Earnings per share change (TTM)
-19.22%
3-year earnings per share growth (CAGR)
-28.20%
What the Analysts think about RLMD
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Relmada Therapeutics stock.
RLMD Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
RLMD Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
RLMD News
AllArticlesVideos
Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
GlobeNewsWire·1 day ago
Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025
GlobeNewsWire·2 weeks ago
UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Relmada Therapeutics stock?
Relmada Therapeutics (RLMD) has a market cap of $12M as of May 09, 2025.
What is the P/E ratio for Relmada Therapeutics stock?
The price to earnings (P/E) ratio for Relmada Therapeutics (RLMD) stock is 0 as of May 09, 2025.
Does Relmada Therapeutics stock pay dividends?
No, Relmada Therapeutics (RLMD) stock does not pay dividends to its shareholders as of May 09, 2025.
When is the next Relmada Therapeutics dividend payment date?
Relmada Therapeutics (RLMD) stock does not pay dividends to its shareholders.
What is the beta indicator for Relmada Therapeutics?
Relmada Therapeutics (RLMD) has a beta rating of 0.41. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.